Focosi D. (ed.) Resistance to Tyrosine Kinase Inhibitors

Springer International Publishing, Cham, Switzerland, 2016, 188 p., ISBN: 978-3-319-46090-1, 978-3-319-46091-8.
Resistance to Targeted Anti-Cancer Therapeutics.
The volume will provide readers with a primer on tyrosine kinase signaling and its importance in cancer.
The reader will be first introduced to common denominators of small-molecule and antibody-derived inhibitors, and with the general phenomemon of resistance.
Then specific reviews will focus on resistance to the most commonly used classes of tyrosine kinase inhibitors, namely BCR-ABL1, FLT3, the HER family members, angiokinase family members, ALK and the Raf/MEK/MAPK pathway.
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells.
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer.
The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview.
Resistance to FLT3 Inhibitors.
Resistance to ALK Inhibitors.
Resistance to Angiokinase Inhibitors.
Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.